.Merck beats profits requirements, increases purchases outlook on strong need for leading medicines like Keytruda CNBCMerck & Co. (MRK US) Defeats Earnings Forecasts as Keytruda Sales Growth BloombergMerck Stock: Pharma Titan Posts Solid End Results, Yet Overview Tumbles Short Client's Service DailyMerck Announces Second-Quarter 2024 Financial Outcomes Yahoo FinanceMerck defeats income as well as purchases assumptions amidst Keytruda strong point, yet supplies combined full-year outlook MarketWatch.